BRAINSTORM CELL THERAPEUTICS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.27 per share for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2013-11-14
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.29.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2012 was $0.16.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2013-09-30 | $0.27 10-Q · filed 2013-11-14 | |||
| 2013-06-30 | $0.27 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $0.29 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $0.16 10-K · filed 2013-03-14 | |||
| 2012-09-30 | $0.16 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $0.00 10-Q/A · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |